Savara Inc. (SVRA) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Savara Inc. (SVRA) Healthcare & Pipeline Overview

Savara Inc. is a clinical-stage biopharmaceutical company specializing in rare respiratory diseases, with a primary focus on advancing molgramostim, an inhaled therapy for autoimmune pulmonary alveolar proteinosis (aPAP), through Phase III clinical trials, positioning it within the competitive biotechnology landscape.

What Is the Investment Thesis for SVRA?

Savara Inc. presents a focused investment opportunity within the rare respiratory disease space, primarily driven by the potential success of molgramostim in treating autoimmune pulmonary alveolar proteinosis (aPAP). With molgramostim currently in Phase III clinical trials, positive results could lead to regulatory approval and subsequent commercialization, representing a significant value driver. The company's focus on rare diseases allows for potential orphan drug designation, offering market exclusivity. However, the investment is subject to clinical trial risks, regulatory hurdles, and the competitive landscape of the biotechnology industry. Successful commercialization and market penetration are also critical for realizing the full potential of molgramostim. Savara's market capitalization of $1.13B reflects current investor expectations regarding the success of its clinical programs.

Based on FMP financials and quantitative analysis

SVRA Key Highlights

Molgramostim is in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP), representing a late-stage clinical asset.

• Savara focuses on rare respiratory diseases, potentially qualifying for orphan drug designation and market exclusivity.
• The company has a market capitalization of $1.13B, reflecting investor valuation of its pipeline and potential.
• Savara operates with a relatively small team of 59 employees, indicating a lean operational structure.
• The company's beta of 0.31 suggests lower volatility compared to the broader market.

Who Are SVRA's Competitors?

SVRA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SVRA's Key Strengths?

Lead product candidate in Phase III clinical development.

• Focus on a rare disease with unmet medical need.
• Potential for orphan drug designation and market exclusivity.
• Experienced management team with expertise in drug development.

What Are SVRA's Weaknesses?

Reliance on a single lead product candidate.

• Limited commercial infrastructure and resources.
• High risk associated with clinical trial outcomes.
• Dependence on regulatory approvals for commercialization.

What Could Drive SVRA Stock Higher?

Announcement of Phase III clinical trial results for molgramostim in aPAP.

• Potential regulatory submission for molgramostim to the FDA.
• Continued enrollment and progress in clinical trials.
• Potential for strategic partnerships or collaborations.

What Are the Key Risks for SVRA?

Negative return on equity (-90.3%) — the business is not currently generating profit on shareholder capital.

• Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Unfavorable clinical trial results for molgramostim.
• Regulatory setbacks or delays in the approval process.
• Competition from other companies developing therapies for aPAP.
• Dependence on successful commercialization of molgramostim.
• Financial risks associated with funding clinical development and commercialization.

What Are the Growth Opportunities for SVRA?

• Expansion into Additional Indications: Savara has the opportunity to explore the potential of molgramostim in treating other respiratory diseases beyond aPAP. This could involve conducting clinical trials to evaluate its efficacy in conditions with similar underlying mechanisms, such as other forms of pulmonary alveolar proteinosis or related lung disorders. Successful expansion into new indications could significantly broaden the market opportunity for molgramostim and drive revenue growth. The timeline for this growth opportunity would depend on the initiation and completion of clinical trials, potentially spanning several years.
• Geographic Expansion: Savara can pursue geographic expansion by seeking regulatory approvals and commercializing molgramostim in markets outside of the United States. This could involve partnering with international pharmaceutical companies or establishing its own commercial infrastructure in key regions, such as Europe and Asia. Geographic expansion would require significant investment in regulatory affairs, marketing, and distribution, but could also unlock substantial revenue potential. The timeline for this growth opportunity would depend on the regulatory approval processes in different countries, potentially taking several years.
• Advancement of Pipeline Candidates: Savara can focus on advancing its earlier-stage pipeline candidates through preclinical and clinical development. This could involve investing in research and development to identify and validate new drug targets, as well as conducting clinical trials to evaluate the safety and efficacy of novel therapies. A successful pipeline expansion would diversify the company's product portfolio and reduce its reliance on molgramostim. The timeline for this growth opportunity would depend on the complexity of the drug development process, potentially spanning several years.
• Strategic Partnerships and Acquisitions: Savara can pursue strategic partnerships and acquisitions to expand its product portfolio, access new technologies, or strengthen its market position. This could involve collaborating with other biotechnology companies to co-develop or co-commercialize therapies, or acquiring companies with complementary assets or expertise. Strategic partnerships and acquisitions can accelerate growth and create synergies, but also involve integration risks and financial considerations. The timeline for this growth opportunity would depend on the availability of suitable partners or acquisition targets.
• Development of Novel Drug Delivery Technologies: Savara can invest in the development of novel drug delivery technologies to improve the efficacy and convenience of its therapies. This could involve exploring new inhalation devices or formulations that enhance drug absorption and distribution in the lungs. Improved drug delivery technologies can differentiate Savara's products from competitors and enhance patient compliance. The timeline for this growth opportunity would depend on the complexity of the technology development process, potentially spanning several years.

What Are SVRA's Competitive Advantages?

• Orphan drug designation provides market exclusivity for rare diseases.
• Proprietary formulations and drug delivery technologies.
• Strong intellectual property protection for its product candidates.
• Expertise in developing therapies for rare respiratory conditions.

What Does SVRA Do?

Savara Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare respiratory diseases. The company's primary focus is on addressing the unmet needs of patients with autoimmune pulmonary alveolar proteinosis (aPAP) and other challenging respiratory conditions. Savara's lead product candidate, molgramostim, is an inhaled formulation of granulocyte-macrophage colony-stimulating factor (GM-CSF), currently in Phase III clinical development for the treatment of aPAP. Molgramostim aims to address the underlying cause of aPAP by stimulating the clearance of surfactant buildup in the lungs. The company's strategic focus on rare respiratory diseases allows it to pursue targeted clinical development pathways and potentially achieve orphan drug designation, which provides market exclusivity and other regulatory benefits. Savara is headquartered in Austin, Texas, and manages its clinical and development programs with a team of experienced professionals dedicated to advancing novel therapies for patients with rare respiratory conditions. The company's evolution has been marked by a commitment to scientific rigor and a patient-centric approach to drug development.

What Products and Services Does SVRA Offer?

• Develops and commercializes therapies for rare respiratory diseases.
• Focuses on autoimmune pulmonary alveolar proteinosis (aPAP) as its primary target.
• Advances molgramostim, an inhaled GM-CSF, through clinical trials.
• Seeks regulatory approvals for its product candidates.
• Conducts research and development to expand its pipeline.
• Manages clinical trials to evaluate the safety and efficacy of its therapies.
• Pursues orphan drug designation for its products to gain market exclusivity.

How Does SVRA Make Money?

• Develops pharmaceutical products through clinical trials.
• Seeks regulatory approval from agencies like the FDA.
• Commercializes approved products through sales and marketing.
• Potentially partners with other companies for distribution or co-development.

What Industry Does SVRA Operate In?

Savara Inc. operates within the biotechnology industry, which is characterized by high levels of innovation, regulatory scrutiny, and competition. The market for rare respiratory diseases is a specialized segment within the broader pharmaceutical market, with increasing attention from both established pharmaceutical companies and emerging biotechs. The competitive landscape includes companies developing therapies for similar indications, as well as those pursuing alternative treatment modalities. Savara's success depends on its ability to navigate the regulatory landscape, demonstrate clinical efficacy, and effectively commercialize its products. The biotechnology industry is subject to evolving market trends, including advancements in drug delivery technologies and personalized medicine.

Who Are SVRA's Key Customers?

• Patients with rare respiratory diseases, particularly aPAP.
• Healthcare providers who treat these patients.
• Hospitals and clinics that administer the therapies.
• Potential pharmaceutical partners for commercialization.

Wall Street analysts project Savara Inc. revenue of about $2.6M for fiscal 2026, with EPS near $-0.46. The estimate reflects 6 contributing analysts.

Savara Inc. has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 8.9% below estimates on average.

Savara Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 7.06 places it in the safe zone, indicating low near-term bankruptcy risk.

Return on equity for Savara Inc. stands at -90.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -72.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -10.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 10.13 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -10.2%, the inverse of the P/E and a quick read on earnings relative to price.

Savara Inc. (SVRA) Valuation Context

Valued at $1.13B, SVRA is classified as a small-cap stock. Relative to its peer group, SVRA's quantitative score of 52/100 is below the peer average of 73/100.

Company Profile

Savara Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Langhorne, US. The company is led by CEO Matthew Pauls. SVRA has traded publicly since 2017.

SVRA Financials

SVRA Latest News

SVRA Analyst Consensus

SVRA MoonshotScore

Latest Savara Inc. Analysis

Common Questions About SVRA (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources